Phuong Vu

Understanding the complexity of p53 in a new era of tumor suppression

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution

A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patients